[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563663":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":23,"locations":33,"responsibleParty":58,"collaborators":60,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":10,"enrollmentInfo":73,"targetDuration":10,"studyType":76,"phases":10,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":85,"whyStopped":10,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Hospices Civils de Lyon","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"High hemolytic group",null,"Lactate Dehydrogenase Level \\> 484 IU\u002FL",[13],"Other: blood sampling",{"label":15,"type":10,"description":16,"interventionNames":17},"Low hemolytic group","Lactacte Dehydrogenase Level less or equal to 484 IU\u002FL",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"blood sampling","3 additional citrate tubes (2.7mL)",[9,15],[24,30],{"name":25,"role":26,"phone":27,"phoneExt":28,"email":29},"Corine Halfon-Domenech, Dr","CONTACT","0033469166550","+33","Carine.HALFONDOMENECH@ihope.fr",{"name":31,"role":26,"phone":10,"phoneExt":10,"email":32},"Philippe CONNES, Pr","philippe.connes@univ-lyon1.fr",[34,49],{"facility":35,"status":10,"city":36,"state":10,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Insitut Hématologique et Oncologique Pédiatrique (IHOPe)","Lyon","69008","France","FR",{"type":41,"coordinates":42},"Point",[43,44],4.84789,45.74906,{"lat":44,"lon":43},[47],{"name":25,"role":26,"phone":48,"phoneExt":10,"email":29},"+33 4 69 16 65 50",{"facility":50,"status":10,"city":36,"state":10,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":51,"geoPoint":53,"contacts":54},"Service de Médecine Interne - Hôpital Edouard Herriot",{"type":41,"coordinates":52},[43,44],{"lat":44,"lon":43},[55],{"name":56,"role":26,"phone":10,"phoneExt":10,"email":57},"Solène Poutrel, Dr","solene.poutrel@chu-lyon.fr",{"type":59,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[61],{"name":62,"class":63},"Laboratoire Interuniversitaire de Biologie de la Motricité (UCBL1) UR7424","UNKNOWN","100563663","relationship-between-biological-phenotype-clinical-severity-of-sickle-cell-disease-and-blood-coagulation-100563663",false,"NCT06619093","Relationship Between Biological Phenotype, Clinical Severity of Sickle Cell Disease, and Blood Coagulation","DREPA COAG","Inclusion Criteria:\n\n* Aged 8 years or older\n* Under clinical follow-up for a diagnosis of sickle cell disease, specifically genotypes S\u002FS, S\u002Fbeta0, or S\u002FC\n* Patient covered by a social security or equivalent health insurance plan\n* Collection of the non-opposition for adults\n* Information of the minor and collection of the non-opposition from both parents\n\nExclusion Criteria:\n\n* Patient who has undergone a transfusion or therapeutic phlebotomy within the 3 months prior to inclusion\n* Patient participating in another interventional research protocol that may interfere with the present protocol (at the investigator\\'s discretion)\n* Patient under guardianship, curatorship, or legal protection\n* Patient subject to a legal protection measure\n* Person admitted to a health or social care institution for purposes other than research","ALL","8 Years",{"count":74,"type":75},200,"ESTIMATED","OBSERVATIONAL","Sickle cell disease is characterized by chronic hemolytic anemia and blood rheological alterations. In addition, blood coagulation abnormalities have been reported in patients with sickle cell disease and hemolysis-derived products could be involved. The investigators hypothesized that patients with sickle cell disease and severe hemolysis (Lactate Dehydrogenase level \\> 484 IU\u002FL) could have an increased risk of hypercoagulable state and subsequent thromboembolic complications.",[79],"Sickle Cell Disease (SCD)",[81,82,83,84],"Hemolysis","Coagulation","Red blood cell","Sickle cell disease","NOT_YET_RECRUITING","2025-01-14",{"date":88,"type":89},"2025-01-15","ACTUAL",{"date":91,"type":75},"2025-02-01",{"date":93,"type":75},"2028-02-01",{"name":5,"class":6},2]